Literature DB >> 7946433

Secondary malignancies following cancer chemotherapy.

P Boffetta1, J M Kaldor.   

Abstract

Many agents used in cancer chemotherapy are known carcinogens. However, few secondary malignancies have been definitely linked to chemotherapy, since studies on this problem are complicated by methodological problems. A causal relationship has been established between alkylating agents and leukaemia and between cyclophosphamide and bladder cancer. The risk of leukaemia peaks at 5-10 years after beginning of chemotherapy and declines steadily after its end. The interaction between chemotherapy and radiotherapy has not been fully clarified, nor has the leukaemogenic potency of individual drugs, although combinations without nitrogen mustard seem to entail a lower risk. Other tumours reported at increased incidence, in particular among Hodgkin's disease patients, for whom a carcinogenic effect of chemotherapy seems plausible, are non-Hodgkin's lymphoma and lung cancer. Other secondary solid tumors have also been reported, but for none of them an independent effect of chemotherapy has been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7946433     DOI: 10.3109/02841869409121767

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  29 in total

1.  Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers.

Authors:  Eric Adjei Boakye; Maggie Wang; Arun Sharma; Wiley D Jenkins; Nosayaba Osazuwa-Peters; Betty Chen; Minjee Lee; Mario Schootman
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

2.  Traditional Chinese medicine versus western medicine as used in China in the management of rheumatoid arthritis: a randomized, single-blind, 24-week study.

Authors:  Yi-Ting He; Ai-Hua Ou; Xiao-Bo Yang; Wei Chen; Li-Yuan Fu; Ai-Ping Lu; Xiao-Ping Yan; Xing-Hua Feng; Li Su; Yue-Jin Song; Sheng-Ping Zeng; Wei Liu; Xian Qian; Wan-Hua Zhu; Ying-Rong Lao; Wei-Hua Xu; Ze-Huai Wen; Xiao-Hong He; Bao-Juan Wang; Geng-Xin Chen; Su-Qin Xue
Journal:  Rheumatol Int       Date:  2014-04-24       Impact factor: 2.631

Review 3.  Chemoprotection of normal tissues by transfer of drug resistance genes.

Authors:  J A Rafferty; I Hickson; N Chinnasamy; L S Lashford; G P Margison; T M Dexter; L J Fairbairn
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

4.  Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?

Authors:  Timothy L Cannon; Dominic W Lai; David Hirsch; Mark Delacure; Andrea Downey; Alexander R Kerr; Michael Bannan; Eleni Andreopoulou; Tamar Safra; Franco Muggia
Journal:  Oncologist       Date:  2012-05-23

5.  Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer.

Authors:  Matteo Pezzoli; Maurizio Bona Galvagno; Guido Bongioannini
Journal:  BMJ Case Rep       Date:  2015-01-14

6.  Concomitant multiple myeloma, gastric adenocarcinoma and Evan's syndrome in a patient presenting with anaemia.

Authors:  Maged Al-Ammari; Soheir Adam
Journal:  BMJ Case Rep       Date:  2016-12-15

7.  Niacin deficiency increases the sensitivity of rats to the short and long term effects of ethylnitrosourea treatment.

Authors:  A C Boyonoski; L M Gallacher; M M ApSimon; R M Jacobs; G M Shah; G G Poirier; J B Kirkland
Journal:  Mol Cell Biochem       Date:  1999-03       Impact factor: 3.396

Review 8.  Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Authors:  L Lennard
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

9.  Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.

Authors:  Takeaki Takenaka; Kuniaki Itoh; Takayo Suzuki; Atae Utsunomiya; Shin Matsuda; Takaaki Chou; Toshiaki Sai; Masayuki Sano; Susumu Konda; Tatsuji Ohno; Chikara Mikuni; Kijoh Deura; Takashi Yamada; Fumi Mizorogi; Haruhisa Nagoshi; Masao Tomonaga; Tomomitsu Hotta; Kohichi Kawano; Keitaro Tsushita; Masami Hirano; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

10.  Kinetics of DNA Adducts and Abasic Site Formation in Tissues of Mice Treated with a Nitrogen Mustard.

Authors:  Haoqing Chen; Ziyou Cui; Leila Hejazi; Lihua Yao; Scott J Walmsley; Carmelo J Rizzo; Robert J Turesky
Journal:  Chem Res Toxicol       Date:  2020-04-02       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.